|
Match
|
Document |
Document Title |
|
|
US20120021051 |
ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM
A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for...
|
|
|
US20130059000 |
ORAL DELIVERY FOR HEMOGLOBIN BASED OXYGEN CARRIERS
A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three...
|
|
|
US20110195118 |
Process for Producing Oral Dosage Forms With Controlled Release
A process for producing solid oral dosage forms with controlled active ingredient release, comprising a mixture of a) at least one active ingredient, andb) a preformulated mixture of polyvinyl...
|
|
|
US20110091542 |
BACLOFEN AND R-BACLOFEN GASTRORETENTIVE DRUG DELIVERY SYSTEMS
A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release...
|
|
|
US20130039980 |
Time Release Capsule for Beverage
This invention relates to time-release capsules administered in beverage preparations. The present invention may be used for administration of delayed-release flavor or color enhancement of the...
|
|
|
US20100297224 |
NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
The present invention generally relates to pharmaceutical unit dosage forms of NSAIDs and H2-receptor antagonists, in which the H2-receptor antagonist is formulated so as to be released in a...
|
|
|
US20120244218 |
Calcium supplement
An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and a extended release system that maintains the calcium level in the animal's bloodstream...
|
|
|
US20110268795 |
Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease states and conditions
The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release...
|
|
|
US20120263788 |
CONTROLLED RELEASE HYDROCODONE FORMULATIONS
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
|
|
|
US20120244216 |
COATED PHARMACEUTICAL CAPSULE DOSAGE FORM
Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at...
|
|
|
US20100330172 |
CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION
A pharmaceutical formulation comprising desvenlafaxine having an MMD of between about 5 μm and about 100 μm, or a pharmaceutically acceptable salt thereof, and at least one matrix r...
|
|
|
US20120128770 |
TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE
The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the...
|
|
|
US20110300212 |
Pharmaceutical Formulation
The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a...
|
|
|
US20120141583 |
ALCOHOL RESISTANT DOSAGE FORMS
Opioid controlled release formulation resistant to alcohol extraction of the opioid.
|
|
|
US20120135074 |
High-Strength Testosterone Undecanoate Compositions
The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the present...
|
|
|
US20110217371 |
CONTROLLED-RELEASE MICROPARTICLES AND METHOD OF PREPARING SAME
Disclosed is a controlled-release microparticle: including a matrix comprising a pharmacologically active component; and a controlled-release layer comprising a substance which forms a...
|
|
|
US20120070494 |
Treatment for Attention-Deficit Hyperactivity Disorder
A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and...
|
|
|
US20110008425 |
Treatment for Attention-Deficit Hyperactivity Disorder
A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and...
|
|
|
US20110059169 |
Method and Composition for Administering an NMDA Receptor Antagonist to a Subject
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
|
|
|
US20110159089 |
ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier...
|
|
|
US20110150991 |
ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier...
|
|
|
US20110150990 |
ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier...
|
|
|
US20110150971 |
ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier...
|
|
|
US20120328697 |
Controlled Release Solid Dose Forms
The present invention is directed to a solid dose form comprising a film coating composition encapsulating a core, wherein: (i) the core comprises an active ingredient comprising at least one of a...
|
|
|
US20120231073 |
DEXLANSOPRAZOLE COMPOSITIONS
Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis...
|
|
|
US20110195101 |
Polysaccharide Capsules and Methods of Preparation
The present invention is directed to seamless capsules and methods for making seamless capsules having a high oil content as described herein. More specifically, the present invention is directed...
|
|
|
US20120156289 |
Biodegradable Osmotic Pump Implant For Drug Delivery
The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a...
|
|
|
US20120021053 |
CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
|
|
|
US20120021052 |
CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic,...
|
|
|
US20110244034 |
SUSTAINED RELEASE DRUG DELIVERY SYSTEM
The invention discloses a controlled release dosage form comprising a therapeutically effective amount of a pharmaceutically active agent, illustrated by Acyclovir, that would release in about 12...
|
|
|
US20110305754 |
CONTROLLED RELEASE MICRO-CAPSULE FOR OSTEOGENIC ACTION
The present invention relates to a microcapsule for controlled release of flavanoid compound and a process for preparation thereof. The microcapsule comprising a core particle consisting of a...
|
|
|
US20130078304 |
CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS
The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form...
|
|
|
US20110123612 |
PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER
The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient...
|
|
|
US20090087484 |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
A formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules includes a permeation enhancer, a hydrophilic macromolecule, and a carrier such as...
|
|
|
US20110287095 |
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form...
|
|
|
US20110150989 |
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form...
|
|
|
US20120141584 |
Multilayer Minitablets
Multilayer minitablets for oral administration of an active pharmaceutical ingredient which release the active pharmaceutical ingredient at different pH ranges and/or in different release profiles...
|
|
|
US20110250269 |
HIGHLY EFFICIENT AND LONG-ACTING SLOW-RELEASE FORMULATION OF POORLY SOLUBLE DRUGS AND PREPARATION METHOD THEREOF
A high-efficacy, long-acting, slow-release formulation of the poorly soluble drug, comprising solid dispersion of the poorly soluble drug, silica nanoparticles loaded with the poorly soluble drug,...
|
|
|
US20080069872 |
Multi-Layered Controlled-Release Methylphenidate Pellet
The present invention relates to a type of controlled-release multilayered methylphenidate pellet that does not need to be combined with another type of pellet. It allows the maintenance of...
|
|
|
US20100291201 |
COATED PHARMACEUTICAL CAPSULE DOSAGE FORM
Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at...
|
|
|
US20090196921 |
Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition
Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain of...
|
|
|
US20080020018 |
Combination Products
A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active...
|
|
|
US20110104269 |
COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS
An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained...
|
|
|
US20080044442 |
Container for an Inhalation Anesthetic
The specification and drawings describe and show one preferred embodiment or a small number of preferred embodiments of the present invention in the form of a container constructed from or lined...
|
|
|
US20100310650 |
Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation
A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process...
|
|
|
US20090214642 |
COATED FORMULATIONS FOR TOLTERODINE
A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing...
|
|
|
US20110177164 |
Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
A stabilized pharmaceutical composition of benzimidazole compounds preferably amorphous form of esomeprazole and a process for preparing the same. The pharmaceutical compositions formulated into...
|
|
|
US20110111022 |
PHARMACEUTICAL FORMULATION
The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an...
|
|
|
US20100215739 |
LOW DOSE TOPIRAMATE / PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF
A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in...
|
|
|
US20080102115 |
Modified coagulation factor IX polypeptides and use thereof for treatment
Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral...
|